<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Internal Medicine: Endocrinology Topic Collection</title>
    <link>http://archinte.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 13 May 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 14 May 2013 18:44:55 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archinte.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archinte.jamanetwork.com</webMaster>
    <item>
      <title>Adulterated Sexual Enhancement Supplements More Than Mojo  Adulterated Sexual Enhancement Supplements </title>
      <link>http://archinte.jamanetwork.com/article.aspx?articleID=1687522</link>
      <pubDate>Mon, 13 May 2013 00:00:00 GMT</pubDate>
      <author>Cohen PA, Venhuis BJ. </author>
      <description>&lt;span class="paragraphSection"&gt;Over the last 5 years the US Food and Drug Administration (FDA) has identified more than 330 dietary supplements adulterated with active pharmaceuticals. Although the FDA has recalled some of these products, recent research suggests that, even after the recalls, products remain available over the Internet and on store shelves. One of the largest categories of tainted supplements are those sold to enhance sexual performance. A combination of manufacturer scrupulousness and consumer demand has created a huge market for dangerous sexual enhancement supplements. One recent example, Rock Hard for Men (manufacturer unknown), sold as a “natural” supplement, actually contains 2 potent prescription drugs—a phosphodiesterase-5 (PDE-5) inhibitor, tadalafil, and a sulfonylurea, glyburide. This combination of medications is of particular concern because a very similar combination discovered in other sex supplements has already led to more than a dozen deaths. If physicians, legislators, and regulators do not act decisively soon, more deaths may follow.&lt;/span&gt;</description>
      <prism:startingPage xmlns:prism="prism">1</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">3</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jamainternmed.2013.854</prism:doi>
      <guid>http://archinte.jamanetwork.com/article.aspx?articleID=1687522</guid>
    </item>
    <item>
      <title>Error in Table in: Communication and Medication Refill Adherence: The Diabetes Study of Northern California</title>
      <link>http://archinte.jamanetwork.com/article.aspx?articleID=1687641</link>
      <pubDate>Mon, 13 May 2013 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;Error in Table. The Original Investigation titled “Communication and Medication Refill Adherence: The Diabetes Study of Northern California,” published in the February 11, 2013, issue (2013;173[3]:210-218) contained an error in Table 3 on page 215. The first column heading should just read “Measure” rather than “CAHPS Measure.”&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">173</prism:volume>
      <prism:number xmlns:prism="prism">9</prism:number>
      <prism:startingPage xmlns:prism="prism">731</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">731</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jamainternmed.2013.6768</prism:doi>
      <guid>http://archinte.jamanetwork.com/article.aspx?articleID=1687641</guid>
    </item>
  </channel>
</rss>